Key result
Bivalent SF-LNP mRNA vaccine protects mice and hamsters against RSV and SARS-CoV-2 Omicron infections.
Why the study?
SARS-CoV-2 and RSV cause severe respiratory illness globally, and co-infection with multiple viruses greatly increases clinical severity.
Does a bivalent mRNA vaccine (SF-LNP) induce immune responses and protect against RSV and SARS-CoV-2 infections in animal models?
Does a bivalent mRNA vaccine (SF-LNP) induce immune responses and protect against RSV and SARS-CoV-2 infections in animal models?
A novel bivalent mRNA vaccine candidate (SF-LNP) successfully induced immune responses and protected against both RSV and SARS-CoV-2 in preclinical animal models.
Does not inform clinical vaccination; leaves open human efficacy of bivalent mRNA against RSV and SARS-CoV-2.
As the world continues to confront severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus (RSV) is also causing severe respiratory illness in millions of infants, elderly individuals, and immunocompromised people globally. Exacerbating the situation is the fact that co-infection with multiple viruses is occurring, something which has greatly increased the clinical severity of the infections. Thus, our team developed a bivalent vaccine that delivered mRNAs encoding SARS-CoV-2 Omicron spike (S) and RSV fusion (F) proteins simultaneously, SF-LNP, which induced S and F protein-specific binding antibodies and cellular immune responses in BALB/c mice. Moreover, SF-LNP immunization effectively protected BALB/c mice from RSV infection and hamsters from SARS-CoV-2 Omicron infection. Notably, our study pointed out the antigenic competition problem of bivalent vaccines and provided a solution. Overall, our results demonstrated the potential of preventing two infectious diseases with a single vaccine and provided a paradigm for the subsequent design of multivalent vaccines. As the world continues to confront severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus (RSV) is also causing severe respiratory illness in millions of infants, elderly individuals, and immunocompromised people globally. Exacerbating the situation is the fact that co-infection with multiple viruses is occurring, something which has greatly increased the clinical severity of the infections. Thus, our team developed a bivalent vaccine that delivered mRNAs encoding SARS-CoV-2 Omicron spike (S) and RSV fusion (F) proteins simultaneously, SF-LNP, which induced S and F protein-specific binding antibodies and cellular immune responses in BALB/c mice. Moreover, SF-LNP immunization effectively protected BALB/c mice from RSV infection and hamsters from SARS-CoV-2 Omicron infection. Notably, our study pointed out the antigenic competition problem of bivalent vaccines and provided a solution. Overall, our results demonstrated the potential of preventing two infectious diseases with a single vaccine and provided a paradigm for the subsequent design of multivalent vaccines.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2024) studied RSV and SARS-CoV-2 infections. SF-LNP bivalent mRNA vaccine was evaluated on Protection from RSV and SARS-CoV-2 Omicron infection. The SF-LNP bivalent mRNA vaccine induced specific immune responses and effectively protected BALB/c mice from RSV infection and hamsters from SARS-CoV-2 Omicron infection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: